Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

November 2, 2023

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 62 min

Earnings Call Speaker Segments

Lawrence Keusch

executive
#1

Hello, everyone, and good morning. Thank you for joining us for Teleflex Incorporated's earnings conference call covering the third quarter of 2023. You can find the press release and the slides that go with this call on our website, teleflex.com. I want to point out that those viewing via webcast may move the presentation slides forward themselves, so just follow along with the presentation as we make our way through the call. Also, please remember that a replay will be accessible on our website. Anyone who wants to listen to the replay can find the details in our press release from this morning. Joining us today are Liam Kelly, our Chairman, President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom will each deliver prepared remarks, and following that, we'll take your questions. Before we begin, please note that some topics covered on this conference call will contain forward-looking statements regarding future events, as described in the slides available in the Investor Relations section of the Teleflex website. We'd like to caution you that these statements are indeed forward-looking and involve risks and uncertainties, so actual events or results could differ materially. Things that might make real outcomes or occurrences turn out substantially different cover, though aren't restricted to, the items mentioned in the release we put out today, plus the documents we submit to the SEC, such as our Form 10-K, which you can find on our site. At this point, I'll hand things over to Liam so he can share what he has to say.

Liam Kelly

executive
#2

Thanks, Larry, and hello everybody. I'm glad to be here with you this morning. Today's call will cover our Q3 performance, the Palette Life Sciences deal we've completed, and what we're projecting financially for 2023. Moving on to Q3. Teleflex posted revenues of $746.4 million, which is up 8.7% compared with the same period last year, and 7.4% higher when measured on a constant currency basis. Adjusted EPS for the third quarter came in at $3.64, representing an 11.3% gain versus a year ago. Over the course of Q3, macro conditions and healthcare utilization trends were either steady or getting better; within acute care, the setting that makes up our biggest market, utilization in Q3 moved back in line with typical seasonal patterns. Looking at the broader economic picture, during Q3 we observed material inflation and supply chain conditions that were steady to improving on a quarter-over-quarter basis. Broadly speaking, these trends are consistent with what we anticipated for the year. Let's now take a closer look at how revenue came in for Q3. I'll start by going through the geographic segment results for Q3. Every growth figure I mention reflects constant currency, except where I say otherwise. The Americas brought in $428.2 million, a 5.5% year-over-year improvement. We were especially pleased with how our Surgical and Interventional businesses performed. EMEA generated $142.7 million, which was 4% higher than a year ago. Interventional drove the growth this quarter, and our remaining businesses delivered balanced results; now let's look at Asia. Revenue there reached $93.2 million, up 17.1% from the prior year. Across most of the region in Q3, demand held steady. China's revenues grew by more than 20% year-over-year, reflecting healthy underlying demand. Because of the particular product portfolio we have, government-led anticorruption efforts have had no effect on our China business. Let's shift now to Q3 revenues broken out by global product category. Any discussion of global product category growth for Q3 will likewise be on a constant currency basis. Beginning with Vascular Access. Revenue rose 0.3% to $169.9 million. The quarter took a hit, as anticipated, from the Endurance catheter recall we disclosed earlier. Early launch efforts for our next-generation Arrow VPS Rhythm DLX navigation device, along with the new Arrow PICC pre-loaded with the NaviCurve Stylet, keep drawing favorable customer feedback and system placements. And we achieved double-digit growth in our underlying PICC business. Now on to Interventional Access. Revenue reached $134.1 million, climbing 22.4% year-over-year; throughout the quarter, we kept advancing our complex PCI and emerging structural heart portfolios. Balloon pumps, access enclosure, uncontrolled and MANTA made significant contributions to growth this quarter. Shifting to Anesthesia. Revenue fell 1.3% from a year ago to $97.6 million. As anticipated, the ET Tube recall we previously announced weighed on year-over-year growth; in our Surgical business, revenue totaled $112.8 million, rising 20.6% versus a year ago. Among our bigger franchises, ligation, staplers and instruments stood out as growth drivers. For 2023, we now anticipate Standard Bariatrics' Titan Stapler revenues landing in the teens. When it came to Interventional Urology, we saw revenue of $73.6 million, which marked a 6.8% decline compared to the same period last year. Within the U.S., UroLift's biggest hurdle continues to be the office setting. We're still working to bring stability to that portion of the business. Looking outside the U.S., our attention remains on growing UroLift revenue in Japan, and in China, the early stages of our launch have gone according to plan. OEM delivered another strong quarter, with revenues climbing 14% versus a year ago, reaching $82.3 million. Gains during the quarter came from across the board in our portfolio, microcatheters included. For the third quarter, Other revenue rose 5.3% year-over-year to $76.1 million. Regarding those Other revenues, Medline has let us know that they can now exit the MSA sooner in 2023 than we had originally expected. Our expectation now is that the MSA will end earlier in December instead of on December 31st. Later in this call, Tom will provide an update on what this means financially. That wraps up what I have to say about third quarter revenue performance. Now moving to a few other business updates. On October 10th, we shared that we had completed the acquisition of Palette Life Sciences, a privately held company, for an upfront cash payment of $600 million at closing, plus as much as an additional $50 million if certain commercial milestones are met. Palette's product portfolio, and Barrigel in particular, will pair well with the UroLift system, addressing the top two conditions in urology care, BPH and prostate cancer. Barrigel is a rectal spacer that stands out from others. It's simple to sculpt once positioned between the prostate and rectum, and it lets the physician reliably protect healthy rectal tissue ahead of radiation therapy. The global market for rectal spacers is substantial and expanding. According to the American Cancer Society, 288,000 new prostate cancer cases will occur in the U.S., with incidence rising 3% annually. On top of that, growing adoption of hypofractionation radiation therapy is fueling demand for rectal spaces to safeguard healthy tissue. Strategically speaking, bringing Palette's portfolio on board complements our robust position in treating benign prostate enlargement and helps broaden the clinical scope of our interventional urology business. Notably, the majority of rectal space replacements are performed by urologists, which means we can take advantage of our current call point. Our urology sales organization is large and well-established, and it will be strengthened by Palette's clinical know-how in using rectal spacing for radiation therapy in prostate cancer treatment. This acquisition will also let Teleflex connect with additional specialists in fields such as radiation oncology, female urology and pediatric urology. We'll roll out robust peer-to-peer education, a focus on patient awareness and take advantage of best practices. We also anticipate that interest in rectal spaces will create chances to cross-sell UroLift, even though those synergies haven't been factored into our acquisition model. Lastly, Barrigel has already built brand success, which positions Teleflex to invest effectively and grow within a major new market. Looking at it through a financial lens, we anticipate that this acquisition will add to revenue growth and adjusted gross margin right away, and it should boost our adjusted operating margin in the near term. Turning to GLP-1 drugs, a subject investors have been focused on for the last couple of quarters. We keep reviewing clinical data and tracking how GLP-1s are being used so we can gauge any potential exposure for Teleflex. We have examined the markets we operate in. And, as of right now, we do not anticipate GLP-1 having a material direct effect on Teleflex's diversified product portfolio. Even though our biggest exposure is Standard Bariatrics with the Titan Stapler, revenue from this product is projected to represent under 1% of Teleflex's total revenue in 2023. During the last two quarters, we have observed an effect on sleeve gastrectomy volumes stemming from interest in GLP-1s. It is worth noting that although the SELECT trial demonstrated a 20% reduction in major adverse cardiac events across five years, a recent study from the Cleveland Clinic, presented at the American Society for Metabolic and Bariatric Surgery 2023 Annual Scientific Meeting, demonstrated that bariatric surgery has been linked to a 42% lower risk of major adverse cardiac events.

Liam Kelly

executive
#3

Although we still anticipate a certain amount of weakness in bariatric surgery case numbers, our emphasis on taking market share should allow us to compensate for that. Throughout the quarter we stayed busy securing renewed approvals and instructing surgeons; we likewise conducted a thorough examination of our interventional business in order to judge what effect GLP-1s might have, given what the SELECT study demonstrated — namely an absolute decrease of 1.6% in the rate of major adverse cardiac events, moving from roughly 8% down to 6.4% across five years. If you look at which categories of events the study counted as MACE and the period of follow-up involved, the yearly decline in those events comes to tens of basis points. That is, in reality, a fairly modest effect. On top of that, given that patients on GLP-1s might survive longer, the drugs could simply postpone cardiac events rather than prevent them. Furthermore, demographic trends continue to be a strong force, with populations around the world growing older. For those reasons, we do not anticipate GLP-1s will materially affect our Interventional business. Taking a wider view, we offer additional surgical products to bariatric surgeons, such as metal ligation clips and closure devices. The revenue tied to those items within this surgical specialty, however, means little to Teleflex. In fact, the great bulk of our surgical products get used in general, cardiac, urology and gynecological procedures, and GLP-1 usage is not anticipated to affect them much. Through our vascular and interventional business units, Teleflex likewise markets hemodialysis catheters; altogether, North American hemodialysis catheter sales represent under 1% of Teleflex revenues, and most of those are employed to treat acute kidney injury, or AKI, which GLP-1 use is not anticipated to affect; estimates suggest AKI arises in as many as 67% of patients admitted to the intensive care unit, with the overwhelming majority of cases unconnected to chronic kidney disease. Among hospitalized patients, frequent causes of AKI include severe infection, low blood pressure and blockages of the renal tract, and it frequently reverses. Adding together the businesses just described plus estimates for other separate product categories, combined sales for products carrying possible direct exposure to greater GLP-1 drug use comes to roughly 1% to 2% of Teleflex revenues. Even so, the real effect ought to be smaller than that, since GLP-1 drug use might cut back some usage yet would be unlikely to wipe out entirely the demand for the products we have exposed. Our extremely diversified product portfolio centers mainly on critical carrier procedures. Consequently, we estimate that more than 98% of Teleflex revenues ought not to be directly affected by greater GLP-1 drug usage. Going forward, we will keep assessing clinical data and tracking GLP-1 usage so as to gauge any potential exposure for Teleflex. Turning to a update on our Interventional Access business. We are happy to report that we have reached the final phases of completing the commercial launch of the Wattson Temporary Pacing guidewire. Wattson serves as a distinctive bipolar guidewire, purpose-built for TAVR and BAV cases. It's designed by engineers to lower the chance of ventricular perforation and to give doctors confidence in capture while rapid pacing is underway. Functioning as both a delivery guidewire and a pacing wire, Wattson fits alongside our growing structure and heart lineup, which already features demand in large foreclosure device, plus the Langston Dual Lumen, used for contrast delivery and pressure measurement. Momentum is building for us, with emphasis placed on complex PCI within structural heart. Notably, our innovation engine keeps running, and over the years ahead we'll bring several new products to market; that wraps up my prepared remarks. At this point, I'd like to hand the call over to Tom, who will walk through our third quarter financial results in greater detail. Tom?

Thomas Powell

executive
#4

Thank you, Liam, and good morning to everyone. Since we already went over how the company performed on revenue, I'll start with margins. Adjusted gross margin came in at 59.4% for the quarter, which is up 70 basis points from the same period a year ago. That year-over-year gain came mainly from favorable pricing, advantages realized through cost improvement programs, and reduced expenses tied to logistics and distribution, though these were partly offset by ongoing cost inflation as well as adverse movements in foreign exchange rates. In the third quarter, adjusted operating margin reached 27.2%. The 30 basis point improvement compared with last year resulted from gross margin flow-through, partly offset by more headcount and higher employee-related expenses, investments aimed at growing the business, and the inclusion of Standard Bariatrics operating expenses. Net interest expense came to $15.7 million for the third quarter, up from $13.2 million in the comparable period last year. That year-over-year rise in net interest expense is a reflection of higher interest rates relative to the prior year and a larger average debt balance drawn to finance the Palette acquisition, partly offset by greater interest income. Our adjusted tax rate during the third quarter of 2023 was 8%, versus 9.8% a year earlier. The decline in our adjusted tax rate compared with last year stems mainly from a reduction in tax costs tied to a US tax law that mandates capitalization of R&D expenses. On the bottom line, adjusted earnings per share for the third quarter was $3.64, representing an 11.3% increase over the prior year. Now I'll move to a few balance sheet and cash flow highlights. Cash flow from operations across the nine months was $372.4 million, compared with $244.4 million in the same period last year. That $128 million increase was driven primarily by favorable operating results, reduced tax payments, and favorable working capital changes. Those favorable working capital changes largely reflected lower inventory purchases, which stemmed from the inventory buildup last year caused by heightened global supply chain volatility. Now on to the balance sheet. Including the Palette Life Sciences acquisition, our financial position stays sound and keeps giving us flexibility to carry out our disciplined capital allocation strategy. As of the end of the third quarter, our cash balance stood at $881.5 million, versus $292 million at the close of 2022. This cash increase is mainly the result of $600 million of cash held on the balance sheet to fund the Palette Life Sciences acquisition in October 2023. Net leverage at quarter end was roughly 1.4 times, still comfortably under our 4.5 times covenant. On a pro forma basis, net leverage for the third quarter including Palette was about 2.1 times; so now let's turn to financial guidance. Beginning with the Palette Life Sciences acquisition, which closed on October 10th, ahead of our December 1st assumption; for the full year of 2023, we still anticipate Palette net revenue of approximately $56 million on a stand-alone basis. We now expect the transaction to be roughly $0.25 dilutive to the company's adjusted earnings per share in 2023, compared with dilution of $0.15 previously. When we look at 2023, the incremental impact comes mainly from increased interest costs, plus additional operating expenses tied to the transaction closing sooner than planned. As for 2024, our outlook for Palette remains unchanged — we still expect net revenue growth versus the prior year in the high-teens or low 20% range. We also continue to anticipate the deal will dilute the company's adjusted earnings per share by $0.35 in 2024. Starting in fiscal year 2025, the transaction should become increasingly accretive to adjusted EPS. Now for an update on the manufacturing transition services agreement with Medline related to our divestiture of certain respiratory assets: Medline has informed us that they plan to terminate the MSA sooner than the December 31, 2023 end date we previously expected. Because of this early termination of the MSA, our revised 2023 constant currency revenue guidance now accounts for a sales loss of roughly $4 million relative to what we had guided before. Let's move to our updated 2023 outlook. We are raising our 2023 constant currency revenue guidance to 6.4% to 6.6%, which represents a 90 basis point increase at the low end and a 35 basis point increase at the high end. It's worth noting that the revenue lost from the MSA's unexpected early termination in 2023 offsets a little under half of the additional revenue from the Palette acquisition closing sooner than anticipated, which means the bulk of the constant currency guidance increase came from strong operational performance in the third quarter along with our favorable view of the fourth quarter. Now on foreign exchange: we are now assuming roughly $4 million, or 15 basis points, of headwind to revenue from foreign exchange in 2023. That's versus our prior guidance, which had assumed an approximately $8 million tailwind to GAAP revenue growth in 2023. Our updated foreign exchange guidance for 2023 incorporates the actual rates from the third quarter and now assumes current foreign exchange rates, including a euro-dollar exchange rate of $1.05 for the fourth quarter. Taking into account this revised foreign exchange outlook, we expect reported revenue growth of 6.25% to 6.45% in 2023, which implies a dollar range of $2,966 million to $2,971 million. Now on to margins. We are increasing 2023 gross margin guidance by 25 basis points at both the low and high end of the range, to 59.25% to 59.75%. Because of the earlier than expected close of the Palette acquisition and the incremental operating expenses that come with it, we now expect operating margin in the range of 26.25% to 26.5% for 2023. Below the line, we now expect net interest expense of approximately $76 million in 2023. The modest reduction in 2023 guidance reflects higher net interest expense from the earlier-than-anticipated close of the Palette acquisition, offset by better-than-expected performance in the third quarter and debt pay down in the fourth quarter. For 2023, we now anticipate a tax rate of roughly 10%. When it comes to adjusted earnings per share for 2023, we're tightening our guidance to between $13.30 and $13.50. The revised adjusted EPS outlook takes into account strong operating performance, such as third-quarter results that came in above what we had expected, and this was partly offset by an extra $0.10 of dilution tied to the Palette acquisition because it closed early, along with about $0.05 stemming from shifts in foreign exchange rates compared with our previous guidance, plus the MSA ending sooner than we had anticipated. While quarterly guidance isn't something we offer, to help with your modeling, we anticipate fourth-quarter reported revenues falling between $765 million and $771 million. That figure reflects the effect of five fewer selling days, which works out to about $53 million, partly offset by a $3.6 million year-over-year benefit from foreign exchange. That wraps up my prepared remarks, and I'd like to hand things back to Liam now for his closing commentary.

Liam Kelly

executive
#5

Thanks, Tom. To wrap up, I want to emphasize three main points from Q3 2023. To begin with, durable growth during that third quarter came from our diversified portfolio and worldwide reach. Our execution is still solid; new products are being introduced, and healthy margins continue. Next, with that robust Q3 showing plus a macro backdrop that's stable to improving, we're in a good spot to hit the updated financial guidance we've provided for 2023. As we get ready to finish the year, our revised 2023 guidance puts us on track for constant currency growth exceeding 6%. And third, we'll stay focused on the strategy that fuels durable growth; we'll put money into organic growth possibilities and push innovation, widen our margins and carry out our disciplined approach to capital allocation so long-term value creation is strengthened. The completion of the Palette acquisition has us excited. We think this deal will contribute meaningfully to our growth over the years ahead, deliver immediate accretion to adjusted gross margin and lift our adjusted operating margin in the near term. That's everything in my prepared remarks. At this point, I'd like to hand the call back to the operator for Q&A.

Patrick Wood

analyst
#6

Fantastic, and I really appreciate you fielding my question. On the Interventional side of things, I'm curious, and perhaps to some extent on Surgical as well. First, did you experience any stocking tailwind during the quarter, since the numbers came in so strong? And second, was there any kind of tailwind? Or are you noticing any kind of tailwinds? One of your competitors clearly has a recall underway in their portion of the balloon business; so I'm just wondering whether you picked up a little extra business there? Thanks.

Liam Kelly

executive
#7

Patrick, I appreciate the question very much. To take a broader view for a moment, I'd like to begin by noting that we're extremely happy with the results this quarter, Surgical and Interventional included, both of which beat expectations. As a company, we believe we delivered on every element of our income statement in quarter three. The guidance we've updated is optimistic, and it captures the performance of the three quarters so far along with our confidence in finishing the year strongly. A number of our major franchises, among them the ones you brought up, are doing well. Healthcare utilization has returned to where it stood before the pandemic. And I believe the acute care emphasis of our company is truly paying off. Supply chain inflation is stable to getting better. And with each quarter that passes, our confidence in what we can deliver grows. The one area where I'd say we haven't seen gains is likely the urology office side of service, which continues to be difficult. With all of that as context, we feel very confident in our updated revenue guidance of 6.4% to 6.6%, and in our capacity to hit it. To address your specific questions about Interventional Access and Surgical, no, the growth here was underlying, driven by those businesses; we outperformed in Interventional in a few of our key product portfolios, balloon pumps among them. And in Surgical, ligation stapling did well, and the instrument portfolio did too. As for stocking, no, the third quarter is traditionally a destocking month for distributors, and that's what took place this quarter, just as we would have anticipated; and as for the company that had a recall, they've now — they've returned to the market in fits and starts, and it's a duopoly. So typically, hospitals will settle on one company. They'll use either our pump or their pump. And I think we may have picked up some marginal benefit, but that truly wasn't — that really wasn't what drove the upside in its entirety for the Interventional business. It was multifaceted across a wide swath of the portfolio.

Patrick Wood

analyst
#8

That's really clear. I also appreciate the thoughtful remarks on GLP-1. They were genuinely useful.

Liam Kelly

executive
#9

Okay, Patrick.

Jayson Bedford

analyst
#10

Morning. Sorry to open with a dull numbers question, though perhaps this one's for Tom: how much did the recalls affect revenue and EPS — in both Vascular Access and Anesthesia? And does that carry into Q4?

Liam Kelly

executive
#11

When you say revenue, Jayson, is that what you mean?

Jayson Bedford

analyst
#12

Okay, both then. I believe you said the third quarter had some revenue effect. Is there any way to put a number on that? Also, did the recalls have an EPS effect too? And I'm wondering whether that will happen again in Q4.

Liam Kelly

executive
#13

Right. If you combine the two recalls, Jayson, the revenue hit for the quarter would come to roughly $5-ish million, that's what it would amount to. Looking at the gross margin for both products that were affected, it's likely just slightly under the company average flowing through, somewhere in that vicinity. So that means a bit under 60% gross margin passing through. From that, you could calculate what the EPS impact would be, I'd say. Wouldn't you agree, Tom?

Thomas Powell

executive
#14

The revenue effect is something I'd concur with. As for what the recall costs us, the bulk of that has already been accrued during the year's second quarter.

Liam Kelly

executive
#15

Fair enough.

Thomas Powell

executive
#16

In Q3, the effect was really quite small. Yeah.

Jayson Bedford

analyst
#17

All right. And moving on, a bit more about UroLift. I realize it's only been 30 days, but, Liam, have you noticed any chances for cross-selling between Palette and UroLift?

Liam Kelly

executive
#18

Well, we're at a really early point when it comes to combining the two businesses and integrating them. Quite a few members of the sales force have come back to Teleflex quite happily — they actually came over with Palette. As a result, the UroLift product is already familiar to them. We've received a large number of requests from our current UroLift customer base, asking to try out the Palette Barrigel product, and that's extremely, extremely encouraging. It's still too soon, Jayson, to observe any effect from cross-selling going in the opposite direction — from the Barrigel sales force over to the UroLift business. And once more, like we mentioned during our prepared remarks, that isn't something we've factored into our model, Jayson. Do we believe we'll see some? Yes, possibly, a halo effect will emerge once you can approach certain urologists who previously might not have viewed UroLift as something to consider. But as you're aware, 97% of urologists who treat BPH also treat prostate cancer; and among our UroLift-using urologist base, just 20% of them also use Barrigel products. So there's considerable white space for us to expand into, and the early signs from the inbound interest coming from our base are highly encouraging.

Shagun Singh

analyst
#19

Thanks. I really appreciate you taking my question. I'm trying to get a clearer picture of the underlying growth rate. For Q4, based on my calculations, your ex-FX figure suggests a decline of roughly 50 basis points. I think there's a headwind from selling days, which might account for around 610 basis points. Palette contributes about 130, just from what we've calculated, and MSA could be a 50 basis point headwind, which brings us to 4.8% underlying compared to 7.4% in Q3. So first, is my math right? It does suggest a slowdown from Q3 to Q4 on an underlying basis for stacked two-year growth. I'm curious what's causing that. Is there some conservatism at play? And what does that mean for 2024 and the LRP growth of low-6%? Sorry for all those figures.

Liam Kelly

executive
#20

No, that's fine, Shagun, and thanks again for your question. I'll break it down into a few parts. Our updated guidance is 6.4% to 6.6%. On a constant currency basis, that's 0.4% to 1.2%. Then, considering the billing days, which as you heard from Tom's comments, is $53 million or about 7%, that results in underlying growth of 7.4% to 8.1%. Then, as Tom also mentioned, we've included the Palette that closed earlier and the MSA that leaves earlier. The MSA is around $4 million, which is just under half of what we get from the Palette acquisition. So that's my perspective. I'd say there's no deceleration at all. If you factor in today's account, the days — the low end of our guidance for Q4 would show 7.4% to 7.4%, and the high end would clearly indicate some acceleration; and, as I said in my opening, Shagun, that really reflects our performance over three quarters and our excitement about what's ahead for the fourth quarter. I think we've done quite well over three quarters. This marks the third quarter in a row where we've been able to raise revenue. And I think we've seen a major step up from the start of the year, and I'd like to mention one more figure. At the start of the year, the low end of our guidance range was 4.75%. Now, going into the fourth quarter, the low end of our guidance range is 6.4%, a significant increase.

Shagun Singh

analyst
#21

That's a big help. Now, to follow up regarding the margin side. You're taking on roughly $0.25 of Palette dilution during 2023. Your EPS guidance has been increased; so what's causing this improvement underneath? And any insight into 2024? I believe consensus is expecting 50 basis points of margin expansion? And in the context of your LRP, how should we be thinking about 2024? Thanks for taking the questions.

Thomas Powell

executive
#22

Well, regarding the margin, the main thing driving it is that we're largely seeing favorable pricing, mix, and some manufacturing-related variances in Q3. As anticipated, inflation gets better in Q3, both sequentially and versus a year ago. Foreign exchange was somewhat of a headwind during the quarter relatively — and, honestly, looking back, what was actually a benefit earlier in the year has turned into a headwind of sorts. So those are a few of the drivers we observed in Q3, and we see ongoing improvement and stabilization in the macro environment, so to speak, when it comes to inflation and logistics costs and timing that we anticipate will carry through into Q4 as well. And then when it comes to margins for the coming year, we're still going through our annual planning process and truly aren't in a position right now to give guidance for the coming year at this point.

Analyst

analyst
#23

Hi. Elaine here, filling in for Rich. So, for the first question, I remember on the last call you mentioned that Titan was facing a longer approval process with the VAC Committee. I'm just curious whether things are getting better there. Or could you give us any sense of how that trend is looking? Thanks.

Liam Kelly

executive
#24

Yes. For sure. So when it comes to Titan, let me start by looking at Surgical overall — it was an absolutely really strong quarter, with growth of 20.6%. And as for Titan in particular, you'll remember that between Q1 and Q2, the count of surgeons we were proctoring in Q2 was twice what it was in Q1. In Q3, I can share that we kept proctoring at that same level. That's a solid signal that you're making your way through the value analysis committees, since proctoring a surgeon can't happen before you've gotten through the value analysis committee. It's taking more time than we first expected, but at this point we're on a reasonable cadence of getting through these value analysis committees. And we believe that although Titan will be affected and the market will be affected by GLP-1s, as we mentioned in our prepared remarks, the technology is compelling, and we believe there's a pathway for us to keep taking share. The product is performing very, very well. A number of clinical studies are underway that will show the time efficiency of the Titan stapler relative to other technologies. And we do believe it will be a growth driver for Teleflex over a multiyear period, given our ability to save the surgeon time so they can do a better procedure, achieve better patient outcomes and, ultimately, we think that's what will matter at the end of the day, and this will be a growth driver. The overall market probably won't be as big as we first thought, because of GLP-1s; that's just a fact of life. But our objective here is to take share within the market space, and there's still lots of room for us to grow into and take share.

Analyst

analyst
#25

Excellent, that's quite useful. Thanks. Additionally, regarding OEM, it seemed to be performing well. So, are you confident this pattern will carry into 2024? Thanks.

Liam Kelly

executive
#26

Yeah. So, what we've observed during Q3, plus honestly what the initial month of Q4 has shown us, forms the basis for our guidance. And among all our operations, the one where we enjoy the clearest visibility is OEM, simply because orders get placed ahead of time by their very nature, which provides us with better insight into activity there. I'd say the microcatheter portion of OEM has kept delivering extremely strong results throughout the entire year, including during Q3. And we're confident that OEM will remain a double-digit grower for the foreseeable future, considering the context of certain technologies that are exclusive to Teleflex, along with some of the product development efforts we're pursuing at our innovation centers worldwide alongside key customers.

Thomas Powell

executive
#27

Thank you. Good morning, everyone. Mike Sarcone here, filling in for Matt. Appreciate you taking our questions. Hello, Mike.

Michael Sarcone

analyst
#28

Hi there. I just wanted to ask something else about Standard Bariatrics, and I appreciate all the details you provided regarding how GLP-1s are affecting things. Could you perhaps elaborate a bit on the decline you're observing when it comes to sleeve gastrectomy procedure numbers? Some specific figures would really help. And with that in mind, how much market share do you figure you'll need to pick up just to make up for that drop, compared with what you previously anticipated for those volumes?

Liam Kelly

executive
#29

Well, Mike, that market was approximately $300 million. So nobody really knows where things will land with GLP-1s in the end. That's where we have to begin. My perspective is that near term, sleeves are clearly going to decline; whether this turns out to be a temporary dip will hinge on the results, the longer-term results from GLP-1s, and how well patients tolerate the side effects of those drugs; plus, never overlook the expense. These pharmaceutical alternatives carry a substantial price tag when you stack them against surgery. And I'm aware everyone is worked up over that 20% decrease in major events shown in the SELECT study. To frame that properly, like we mentioned in our prepared remarks, it moves from 8% down to 1.6%. That amounts to a percentage of a percentage, which is a risky method for evaluating anything, as any analyst listening knows, since the actual absolute drop is roughly 1.6%. And, as I noted in my prepared remarks, research from the Cleveland Clinic demonstrated a 40% decrease in those same events when gastric sleeves were used. So I believe clinicians will begin to reassess and weigh everything carefully. What we're observing is fewer procedures among the customers we've converted, no question; however, like I said, that market was $300 million. What's the figure now? A $200 million market, which leaves lots of room, Mike, for us to expand into, since most surgeons would agree that the people receiving a gastric sleeve are the morbidly obese population. And I'm strongly convinced that gastric sleeves — if you ask bariatric surgeons, they'll say the same — will still be around going forward. So expanding within what we might call a $200 million market still represents a meaningful opportunity for Teleflex.

Michael Sarcone

analyst
#30

Excellent. Thank you, Liam. We agree with your point about that roughly 10 to 20 bps annual effect. Now, for my second question, it concerns the ASP pricing you're implementing. Could you possibly put a number on how much price you're raising, and how long that can last, or share your views on your capacity to keep taking price in 2024 and afterward?

Liam Kelly

executive
#31

Yeah, that's a fair question. At this point, we've gone through two years of the cycle, and the majority of our tenders and contracts run on a three-year cycle. So, during this year, we had set out our plan to achieve 50 basis points. I can say we're exceeding that. We're a fair amount above those 50 basis points, comparable to what we achieved a year ago; so, that's a positive story for us. And I believe in the coming year, we'll be in a strong position to deliver another 50 basis points, at minimum positive pricing given the environment. Beyond that, Mike, I expect it will taper off somewhat, since we'll have completed the cycle — the three-year cycle of your standard tenders — and we'll evaluate that at that point in 2025.

Vik Chopra

analyst
#32

Hi there. Morning to everyone. Vik here, filling in for Larry. Appreciate you taking my question. I have two things for you. The first one concerns 2024 — I'd like to know whether that 10% tax rate can hold up, given what's recently shifted in the tax laws? Then for my second question, about your approach to M&A, you just wrapped up the Palette deal, so I'm wondering how much room you still have for more deals, and what effect the current higher interest rate climate is having on how you pursue M&A? Thanks so much.

Liam Kelly

executive
#33

Sure, I'll take the M&A piece first, and after that I'll hand it to Tom for your tax question, Vik; regarding M&A, like we mentioned during our prepared remarks, on a pro forma basis, leverage stands at 2.1 times. That means we've got plenty of firepower. Based on whatever EBITDA an asset might deliver, that would take you close to the $2 billion level of capacity that Teleflex has open to it right now. On the interest rate side, rates were elevated back when we acquired Palette, yet we could still reach our internal cost of capital by year five. We still saw a truly appealing asset. We still saw something that will keep driving Teleflex's transformation forward. It will boost our topline growth. Its margins are genuinely attractive, as we've discussed before; and if another Palette came along tomorrow morning, I wouldn't hesitate for a second. I'd go all in to get it done. Right now, we're in talks with more than a handful of companies; potential prices run anywhere from $100 million up to more than $1 billion. And in my view, the landscape remains quite appealing for businesses like Teleflex that have the balance sheet strength to get deals done. Naturally, with interest rates, we'll stay disciplined. We've stayed disciplined across every cycle. Back when rates were low, we stayed disciplined; now that rates are higher, we'll stay disciplined. That won't change at all. And Tom, if you wouldn't mind, I'll let you field the tax question.

Thomas Powell

executive
#34

Okay. So, at roughly 10%, our tax rate for 2023 is, I'd call it, a really appealing rate. And right now, we're working through the AOP and the plans for the coming year. So, at this point, we aren't able to offer specific guidance for 2024. You know, what I'd say is that the expectation would be for the tax rate to be somewhat higher than where we stand in 2023.

George Sellers

analyst
#35

Hi there, morning, and I appreciate you fielding this. Regarding the Palette deal, and Barrigel in particular, might you share a few specifics about how that sales motion actually works? Also, I believe you said most Barrigel users are urologists, so what does the split look like in greater detail when it comes to radiation oncologists compared with urologists?

Liam Kelly

executive
#36

Thank you, George, and morning to you. Let me reassure you that radiation oncologists are not being overlooked by us; in fact, we have a team whose sole focus is training the rad onc throughout this entire effort. Roughly 70% or more of the procedures are performed by the urologist rather than the rad onc, yet we serve both sides. What matters most with Barrage, George, is how distinctive the product is; because it can be sculpted, you are able to shape it around whatever region needs protection, and for the prostate the goal is shielding the anus, so you can contour it around the prostate and ensure that protection holds. No time limits exist for injecting it. It is extremely easy to see. Assembly takes a single step. There is no need for hydrodissection at all. Should it end up in the wrong spot, which sadly does occur occasionally with certain products available on the market, it can be reversed, and that reversibility is something only this product offers. All of these factors, I believe, make it an attractive option. You are correct, and as I mentioned before, just 20% of the UroLift customers we currently have are using Barrigel. Therefore, for us the focus is genuinely on broadening the market and helping it grow instead of capturing share. Given our presence in that space, this strikes me as a distinctive opening for Teleflex. When it comes to the sales process, after a urologist or a rad onc steps up, some anatomy instruction takes place, and then across four or five cases they receive proctoring and support. Once that is complete, they would be considered fully trained and qualified to place the product.

George Sellers

analyst
#37

All right, that's excellent. That color was quite useful, and I'm grateful for it. Perhaps we pivot somewhat, and maybe ask about QuikClot. Where would you place yourselves in terms of how far along you are at capturing that market possibility? Also, has demand been affected at all by certain international conflicts currently taking place?

Liam Kelly

executive
#38

Well, George, this market sits at $600 million when you look at internal plus external, with roughly a fifty-fifty division; a fresh cardiac indication was just secured by us, which broadened the market by roughly $50 million. That brings the total market to somewhere near $650 million. Broadly speaking, MilTac ranks among our important customers. Owing to certain budget restrictions, it has fallen somewhat short of what we hoped across the year's first three quarters. My expectation is that this could now be corrected, though regrettably so, given events unfolding in various regions globally. Thus, we anticipate a return to the plan we originally set in the fourth quarter, and that is factored into the guidance we have just provided.

George Sellers

analyst
#39

Thank you for the time.

Liam Kelly

executive
#40

All right, George.

Anthony Petrone

analyst
#41

Appreciate you fitting us in. I might stay on Barrigel and also ask about the pipeline. You referenced during the deal announcement $0.15 for 2023 and $0.35. When we add it all up in terms of growth and margin, is there anything you can tell us about how Barrigel is performing? I'm aware they also have two additional products there, Deflux and Solesta, for pediatric indications. What does the overall growth profile of that portfolio look like? And does it add to margins relative to the total company average? Then I have a few follow-ups.

Liam Kelly

executive
#42

Sure. Appreciate that, Anthony. For the entire year, our expectation for Palette is $56 million in 2023. Its growth profile sits in the high-teens and low-20s, and that's our expectation for 2024 as well. On your question about the various pieces driving that growth, I'd say you should concentrate very much on Barrigel. That product accounts for most of the growth. That's where we deliver a great deal of the value, and that's where growth has been — historically has been, for the Barrigel product since its launch, simply because of everything I just walked through a moment ago. As for the product's gross margins, like we've stated before, it benefits Teleflex on an accretive basis. Not only does it benefit Teleflex, it also benefits the high-growth portfolio; and beyond benefiting the high-growth portfolio, it benefits UroLift's margins inside that high-growth portfolio. As most investors know, UroLift's gross margins were in the high-70s, or are in the high-70s, rather. So from a gross margin standpoint, this is a very good transaction; and frankly that's why it commanded a very good price, since strong growth plus strong margins is what drives a larger multiple for an asset. And we continue to expect $0.35 of dilution on an EPS basis for 2024, addressing the other part of your question.

Anthony Petrone

analyst
#43

All right. Then for my second question, I suppose I'll return to Titan and GLP-1. Naturally, right at the start here, plenty of people are discussing near-term challenges facing bariatrics, yet there's talk among those in the field that regarding patients with a contraindication at the extreme top of the BMI range, a number of them might be brought in as they begin taking Ozempic or Mounjaro, and so on, GLP-1; therefore, do you believe that as this cycle unfolds, a tailwind could possibly emerge, even though it will obviously require time? How do you view the possibility that GLP-1 might genuinely grow the bariatric market? Thank you.

Liam Kelly

executive
#44

Honestly, Anthony, my attention isn't on GLP-1s growing the market — that's difficult for me to envision, frankly. In my view, GLP-1s serve as a pathway toward a gastric sleeve, and many surgeons regard it that way. I'm also considering how this affects Titan and how enduring that effect will be, since you must take the pharma indefinitely, and you must have the means to keep paying for the pharma indefinitely. Everything I read indicates that in — should the prices for these GLP-1s remain where they are, the odds of coverage are low. I've talked with quite a few bariatric surgeons, I've talked with the team, and I've talked with our clinical group, and the view is that bariatric surgeries will feel a short-term effect. Yet, as I mentioned before, from Teleflex's standpoint, at least over the coming several years, we aim to deliver superior technology to the gastric sleeve market, which none of us believe is disappearing; it could shrink somewhat, but it isn't disappearing, and there remains a substantial market for us to expand into as a company. Thus, I still believe that despite standard not having the launch we'd hoped for, I still believe that over the longer term it will be a good growth driver for Teleflex, and it will grow into the market. And once we reach our penetration point, we'll see where things stand with GLP-1s, whether it proved to be an air pocket or not. More broadly, what encourages me more is that 98% of Teleflex's — 98% plus percent of Teleflex's portfolio sees no impact from GLP-1. So, I think investors are likely labeling everyone as GLP-1 impacted at present simply because of all the hype surrounding it; but when you break down the various company components and what we know at present, we can see that 98% plus of our company is not impacted.

Samantha

analyst
#45

Hi there, Samantha here, filling in for Matt. We've got one quick thing to ask regarding the MSAs. What's your take — you mentioned a bit about the financials at the top line, but how about the possibility of revenue being lost on both the top and the bottom line?

Liam Kelly

executive
#46

So, on the — just so we're clear, you mean the MSA, the manufacturing service agreement?

Samantha

analyst
#47

Yes, that’s correct.

Liam Kelly

executive
#48

All right. So, as Tom mentioned during his prepared remarks, the early close is going to cost us roughly $4 million in revenue. When it comes to the impact on EPS, it comes to approximately $0.01, give or take.

Thomas Powell

executive
#49

Really tiny.

Liam Kelly

executive
#50

Yes, tiny. So, from an EPS standpoint it's pretty small for this year, and the majority of investors are aware the MSA is entirely gone now, and a full year included roughly $70 million of revenue plus about $0.25 of earnings; that should assist people with their modeling. So, the bigger effect on earnings per share this year is, clearly, the early close of Palette, which runs about $0.10; and then FX, Tom, has cost us I believe roughly another $0.05 or so?

Thomas Powell

executive
#51

That’s correct.

Liam Kelly

executive
#52

Okay.

Samantha

analyst
#53

That’s great. Many thanks.

Craig Bijou

analyst
#54

Morning. Appreciate you taking the questions. I realize we’re at the end, so I’ll stick to one topic. Wanted to ask about MANTA. Liam, I believe you brought it up in your prepared remarks. I don’t think it’s come up in a while. So, just wanted to check in on, you know, some of the momentum there? Was it the rebound in the procedures where MANTA is utilized, or are you seeing improved adoption? And then perhaps just a few thoughts on how MANTA will add to your growth as part of your long-term plan or over the next 2 years?

Liam Kelly

executive
#55

Right, so right now MANTA is obviously rolling out in a lot of different regions and countries. Over the three quarters in Asia, we've seen some solid traction, and Craig, we expect this to be something that drives us for multiple years. There's nothing else like it on the market. Honestly, I don't think we're getting any lift from some kind of surge or a procedural bounce back, because we're still working on gaining share and bringing it to customers who haven't seen it yet. The product's uniqueness continues to deliver solid value for us and will keep driving growth across multiple years. Within that high-growth group, there are some genuinely strong offerings—MANTA is in there, so is the Vidacare portfolio, our PICCs, and Z-Medica. Titan hit a small snag along the way. UroLift also ran into a snag, but these days you've got Barrigel plus the entire Palette line and interventional urology sitting inside that high-growth bucket. So our confidence in MANTA is strong; and I think you've got a point. It draws less attention now than it did back when its journey first began.

Craig Bijou

analyst
#56

Thanks.

Operator

operator
#57

That's every minute we had available for questions today. We're wrapping up today's conference call now. Thanks to each of you for joining us. You're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.